Nature agingHumansGlucagon-Like Peptide-1 Receptor AgonistsNeurodegenerative DiseasesAlzheimer DiseaseDiabetes Mellitus
Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders.
Marwan N Sabbagh, Jeffrey L Cummings, Clive Ballard, Wiesje M van der Flier, Michael T Heneka, Jens Juul Holst, Lotte Bjerre Knudsen, Stephen Salloway, Malú Gámez Tansey, Daniel J Drucker
Published: 202610.1038/s43587-025-01029-3
Abstract
With therapeutic progress in Alzheimer's disease (AD), more molecular and mechanistic targets are coming into focus. Beyond amyloid, emerging targets include tau, neuroinflammation and neurotransmitters. Targeting neuroinflammation in neurodegenerati…
Preview only. Read the full abstract at the source